Home / KEEP BUT DO NOT DISPLAY / Alerts / Sanofi Withdrawing NDA for Lixisenatide

Sanofi Withdrawing NDA for Lixisenatide

Sep 13, 2013
 

Sanofi Withdrawing NDA for Lixisenatide 

Sanofi announced they are withdrawing their New Drug Application (NDA) for their once-daily GLP-1 lixisenatide from the FDA. The combination of lixisenatide and Lantus® (basal insulin), the investigational LixiLan fixed-ratio product, remains on schedule to enter into phase 3 in the first half of 2014.